Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Not yet recruiting 2Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 22Lymphoid 15Myeloid 12Plasma cell 5CNS 2Classical hematology 1

Conditions

Multiple Myeloma 3Smoldering Multiple Myeloma 1Leukemia, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 136Lenalidomide 79daratumumab 77Bortezomib 66pomalidomide 48Cyclophosphamide 48carfilzomib 43Calcium Dobesilate 42Specimen Handling 35Biopsy 32Magnetic Resonance Spectroscopy 29belantamab mafodotin 26fludarabine 23isatuximab 22iberdomide 19dexamethasone acetate 19dexamethasone 21-phosphate 19auricularum 19Melphalan 18talquetamab 17fludarabine phosphate 14elotuzumab 12selinexor 11X-Rays 10tocilizumab 9Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Crizotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Stem Cell Transplantation × Plasma cell × 90 days × Clear all
NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03477539 2026-05-05

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Mayo Clinic

Phase 2 Completed
49 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡